Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4455865 | 0.78 | — | — | |
| SCHEMBL13428539 | 0.78 | — | — | |
| SCHEMBL2712218 | 0.76 | — | — | |
| SCHEMBL16553562 | 0.76 | — | — | |
| SCHEMBL16527446 | 0.76 | — | — | |
| SCHEMBL2185091 | 0.76 | — | — | |
| SCHEMBL15698583 | 0.76 | — | — | |
| SCHEMBL15698650 | 0.76 | — | — | |
| SCHEMBL1439232 | 0.76 | — | — | |
| SCHEMBL4462359 | 0.74 | S1PR1 (0.33) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2341777-B1 | ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS | NOVABAY PHARMACEUTICALS INC (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8722715-B2 | Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions | NovaBay Pharmaceuticals (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722715-B2 | Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions | NovaBay Pharmaceuticals (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722715-B2 | Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions | NovaBay Pharmaceuticals (US) | 2014-05-13 | — | — | US | disclosed |
| EP-2341777-A1 | ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS | NovaBay Pharmaceuticals, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20100137349-A1 | ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS | NOVABAY PHARMACEUTICALS, INC. | 2010-06-03 | — | — | US | disclosed |
| US-20100137349-A1 | ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS | NOVABAY PHARMACEUTICALS, INC. | 2010-06-03 | — | — | US | disclosed |
| WO-2010054009-A1 | ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS | NOVABAY PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137349-A1 | ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS | OXA1L, NISCH, ODC1 | IRAK4 1130/4885MGLL 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.